Antibacterial peptide and application thereof in bacteriostasis and sterilization

By developing the antimicrobial peptide RG14, the problems of high hemolytic activity, poor cytotoxicity and stability of existing antimicrobial peptides in clinical applications have been solved, and the effects of low hemolytic activity, no cytotoxicity and high stability have been achieved, which has expanded its inhibitory effect. Application scope of sterilization in the field of sterilization.

CN118930615AActive Publication Date: 2024-11-12ANHUI UNIV

Patent Information

Application Number
CN202411354248.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-27
Publication Date
2024-11-12
Estimated Expiration
2044-09-27

AI Technical Summary

Technical Problem

The existing antibacterial peptides have problems of high hemolytic activity, poor cytotoxicity and stability in clinical applications, which limits their wide application in the field of antibacterial and bactericidal.

Method used

An antibacterial peptide RG14 has been developed, which has low hemolytic activity, non-cytotoxicity and high stability. It has prepared antibacterial bacterial agents through specific amino acid sequences and amidation modifications, combining a variety of antibacterial and bactericidal components to target Gram-negative Bacteria have broad-spectrum antibacterial activity.

Benefits of technology

The antibacterial peptide RG14 quickly kills a variety of bacteria at low concentrations, has significant antibacterial spectrum and safety. It is suitable for the preparation of antibacterial infection drugs and skin care products, significantly improving its application prospects in the field of antibacterial and sterilization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930615A_ABST
    Figure CN118930615A_ABST
Patent Text Reader

Abstract

The invention provides an antibacterial peptide and application thereof in bacteriostasis and sterilization, and belongs to the technical field of active peptides. The invention provides an antibacterial peptide RG14 which comprises an amino acid sequence as shown in SEQ ID No.1. The antibacterial peptide RG14 has the characteristics of wide antibacterial spectrum and strong antibacterial activity, and is low in hemolytic activity, free of cytotoxicity, high in stability, remarkable in advantage and wide in application prospect. The antibacterial peptide RG14 can inhibit various microorganisms, such as gram-negative bacteria, can be applied to preparation of products with antibacterial and bactericidal effects, and increases the application range of the antibacterial peptide RG14.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of active peptides, and specifically relates to an antimicrobial peptide and its application in bacteriostasis and sterilization. Background Art

[0002] Antibiotic resistance is occurring all over the world. More and more infectious diseases are becoming more difficult to treat or sometimes even untreatable. The development of new antimicrobial drugs has become an urgent issue that needs to be addressed.

[0003] Antimicrobial peptides are a class of polypeptides containing 5 to 50 amino acids with antibacterial effects. They were originally isolated from insects, and later from other animals, plants and humans. They are immune active molecules produced by organisms in the long-term evolution process to adapt to the environment and seek survival. They are important mediators of natural immunity and play an extremely important role in the host's immune defense against pathogen invasion. They are vividly called "natural antibacterial agents." To date, there are 3,940 antimicrobial peptides with different structures. Compared with traditional small molecule antibiotics, antimicrobial peptides have the advantages of fast bactericidal speed, low resistance and multiple anti-infection mechanisms, and have broad application prospects in the research and development of new antibiotics.

[0004] However, existing antimicrobial peptides have good biological activity, side effects such as hemolysis and cytotoxicity, and poor in vivo stability, which make clinical applications difficult. Currently, many drugs are derived from peptide molecules through structural optimization and modification, such as the antihypertensive drug captopril and the anti-hepatitis C drug telaprevir. Structuring antimicrobial peptides from natural sources is also an important direction for future drug design and disease treatment drug research and development. Summary of the invention

[0005] The present invention provides an antimicrobial peptide and its application in bacteriostasis and sterilization. The antimicrobial peptide has high antimicrobial activity, low hemolytic activity, no cytotoxicity and high stability.

[0006] The present invention provides an antimicrobial peptide RG14, wherein the antimicrobial peptide RG14 has any of the following amino acid sequences:

[0007] 1) SEQ ID No. 1;

[0008] 2) an amino acid sequence in which one or more amino acids in SEQ ID No. 1 are substituted, deleted and / or added and which has the same function as SEQ ID No. 1;

[0009] 3) An amino acid sequence that has more than 90% homology with SEQ ID No.1 and has the same function as SEQ ID No.1.

[0010] In a specific embodiment of the present invention, the antimicrobial peptide RG14 is further modified.

[0011] In a specific embodiment of the present invention, the C-terminus and / or N-terminus of the antimicrobial peptide RG14 is amidated.

[0012] The present invention also provides the use of the antimicrobial peptide RG14 in the preparation of an antibacterial and bactericidal agent.

[0013] In a specific embodiment of the present invention, the antibacterial spectrum of the bacteriostatic and bactericidal agent includes Gram-negative bacteria.

[0014] In a specific embodiment of the present invention, the Gram-negative bacteria include at least one of the following: Escherichia coli, Pseudomonas aeruginosa, Shigella castellani, Acinetobacter baumnnii and Clostridium perfringens.

[0015] The present invention also provides an antibacterial and bactericidal product, the active ingredients of which include the antimicrobial peptide RG14 and auxiliary materials.

[0016] In a specific embodiment of the present invention, the active ingredients also include other antibacterial and bactericidal ingredients.

[0017] In a specific embodiment of the present invention, the other antibacterial and bactericidal components include at least one of the following: antibiotics, proteins, polypeptides, plant extracts and cytokines.

[0018] In a specific embodiment of the present invention, the types of the antibacterial and bactericidal products include medicines and skin care products.

[0019] Beneficial effects: The present invention provides an antimicrobial peptide RG14 whose amino acid sequence can be shown as SEQ ID No.1. The antimicrobial peptide RG14 has the characteristics of a broad antimicrobial spectrum and strong antibacterial activity. At the same time, it has been verified that compared with existing antimicrobial peptides, the antimicrobial peptide RG14 has low hemolytic activity, no cytotoxicity and high stability, has significant advantages, and has broad application prospects.

[0020] The antimicrobial peptide RG14 of the present invention can inhibit a variety of microorganisms. For example, in the examples, it was found that the MIC values ​​of the antimicrobial peptide RG14 against Escherichia coli CMCC44102, Pseudomonas aeruginosa CMCC10104, Shigella castellani ATCC12022, Acinetobacter baumnnii ATCC19606 and Clostridium perfringens ATCC13124 were 2.34 μg / mL, 4.69 μg / mL, 4.69 μg / mL, 2.34 μg / mL and 9.38 μg / mL, respectively. It can be used to prepare products with antibacterial and bactericidal effects, thereby increasing the application scope of the antimicrobial peptide RG14. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The bactericidal kinetic results of the antimicrobial peptide RG14 against Escherichia coli in Example 2;

[0022] Figure 2 The hemolytic activity test results of the antimicrobial peptide RG14 in Example 3;

[0023] Figure 3 These are the results of the cytotoxicity assay of the antimicrobial peptide RG14 in Example 3. DETAILED DESCRIPTION

[0024] The present invention provides an antimicrobial peptide RG14, wherein the antimicrobial peptide RG14 has any of the following amino acid sequences:

[0025] 1) SEQ ID No. 1;

[0026] 2) an amino acid sequence in which one or more amino acids in SEQ ID No. 1 are substituted, deleted and / or added and which has the same function as SEQ ID No. 1;

[0027] 3) An amino acid sequence that has more than 90% homology with SEQ ID No.1 and has the same function as SEQ ID No.1.

[0028] The antimicrobial peptide RG14 referred to in the present invention is a linear polypeptide, and its amino acid sequence can be as shown in SEQ ID No.1: RLFGRLRWSLRRWG. The amino acid sequence shown in SEQ ID No.1 can also be subjected to point mutation, such as substitution, deletion and / or addition of one or several amino acids, as long as the function is the same as that of SEQ ID No.1; it can also be an amino acid sequence having more than 90% homology with SEQ ID No.1 and having the same function as SEQ ID No.1, such as 99%, 98%, 97%, 96%, 95%, 94%, 93% or 92% homology.

[0029] In a specific embodiment of the present invention, the C-terminus and / or N-terminus of the antimicrobial peptide RG14 can also be modified. For example, in one embodiment, the C-terminus is amidated, and the specific sequence is: RLFGRLRWSLRRWG-NH2, with a molecular weight of 1859.22 Da and an isoelectric point of 12.60.

[0030] The present invention does not specifically limit the preparation method of the antimicrobial polypeptide RG14, and can be prepared by a variety of methods such as direct synthesis, prokaryotic expression and eukaryotic expression, wherein the prokaryotic expression and eukaryotic expression methods are not specifically limited, and can be expressed based on conventional means in the art, such as inserting the coding gene of the antimicrobial polypeptide RG14 into an expression vector, transforming prokaryotic expression cells or eukaryotic expression cells, and inducing expression. In one embodiment of the present invention, the antimicrobial peptide RG14 is prepared by solid phase synthesis, and then purified by high performance liquid chromatography.

[0031] The present invention also provides the use of the antimicrobial peptide RG14 in the preparation of an antibacterial and bactericidal agent.

[0032] The present invention confirms that the antibacterial spectrum of the antibacterial bactericide includes Gram-negative bacteria, such as: Escherichia coli, Pseudomonas aeruginosa, Shigella castellani, Acinetobacter baumnnii and Clostridium perfringens. In an embodiment of the present invention, the MIC values ​​of the antimicrobial peptide RG14 against Escherichia coli CMCC44102, Pseudomonas aeruginosa CMCC10104, Shigella castellani ATCC12022, Acinetobacter baumnnii ATCC19606 and Clostridium perfringens ATCC13124 are 2.34 μg / mL, 4.69 μg / mL, 4.69 μg / mL, 2.34 μg / mL and 9.38 μg / mL, respectively, and the antibacterial activity is high.

[0033] The present invention also provides an antibacterial and bactericidal product, the active ingredients of which include the antimicrobial peptide RG14 and auxiliary materials.

[0034] In the embodiment of the present invention, the antimicrobial peptide can kill Escherichia coli at a lower concentration in a shorter time; and the antimicrobial peptide has low hemolytic activity at different concentrations, and has no cytotoxicity to a variety of cells, and has high safety. The antimicrobial peptide RG14 provided by the present invention can directly kill pathogens, has significant functions, and acts quickly. RG14 has low hemolytic activity, no cytotoxicity, and high stability, and can be used in the preparation of antibacterial and bactericidal products, such as antibacterial infection drugs or skin care products, especially medical beauty products.

[0035] In a specific embodiment, the antibacterial and bactericidal product of the present invention uses the antimicrobial peptide RG14 or an agent containing the antimicrobial peptide RG14 as the only active ingredient; in other embodiments, multiple active ingredients can also be used, such as including the antimicrobial peptide RG14 or an agent containing the antimicrobial peptide RG14, and other antibacterial and bactericidal ingredients, such as at least one of antibiotics, proteins, peptides, plant extracts and cytokines.

[0036] The antibacterial and bactericidal product of the present invention also includes auxiliary materials, which can be one or more of fillers, wetting agents, adhesives, disintegrants, lubricants and surfactants; wherein the fillers include one or more of starch, powdered sugar, dextrin, lactose, compressible starch, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate and mannitol; the wetting agents and adhesives include distilled water, ethanol, starch slurry, sodium carboxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose and ethyl cellulose, hydroxypropyl methyl cellulose, gelatin solution, sucrose solution, polyvinyl pyrrolidone (PVP) aqueous solution or alcohol solution; the disintegrant includes one or more of dry starch, sodium methyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone and cross-linked sodium carboxymethyl cellulose; the lubricant includes one or more of magnesium stearate, micropowder silica gel, talc, hydrogenated vegetable oil, polyethylene glycols and magnesium lauryl sulfate; the surfactant includes sodium lauryl sulfate.

[0037] The present invention does not specifically limit the preparation method of the antibacterial and bactericidal product. The product can be prepared according to conventional methods in the art based on the type of active ingredients and the selection of auxiliary materials.

[0038] In order to further illustrate the present invention, an antimicrobial peptide provided by the present invention and its application in antibacterial and bactericidal activities are described in detail below in conjunction with examples, but they should not be construed as limiting the scope of protection of the present invention.

[0039] Example 1

[0040] Synthesis and purification steps of antimicrobial peptide RG14:

[0041] 1. According to the designed amino acid sequence: RLFGRLRWSLRRWG-NH2, a crude polypeptide was synthesized by solid phase synthesis;

[0042] 2. The crude polypeptide is desalted and purified by HPLC reverse phase column chromatography to identify its purity. The specific method is as follows:

[0043] 0.1 mg of the crude polypeptide prepared in step 1 was dissolved in 1 mL of ultrapure water containing 0.1% trifluoroacetic acid. If there were insoluble impurities, the mixture was filtered with a 0.45 μm filter membrane. The mobile phase A was 0.1% trifluoroacetic acid-water, and the mobile phase B was 0.1% trifluoroacetic acid-acetonitrile. Sample loading was started after the baseline was stable, and the sample loading volume was 50 μL. The chromatographic column was a silica gel alkyl bonded phase C18 column (4.6 mm×300 mm, particle size 5 μm, pore size 100A). A binary mobile phase gradient elution system was used for gradient elution, that is, within 30 minutes, the content of mobile phase B in the eluent increased linearly from 0% to 80%, the flow rate was 1 mL / min, the detection wavelength was 215 nm, and the concentration was measured at 25° C. until the purity of the polypeptide was not less than 95%, thereby obtaining a purified polypeptide, namely, the antimicrobial peptide RG14.

[0044] 3. Determine the antimicrobial peptide RG14 obtained in step 2 by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF), the specific method is as follows:

[0045] The antimicrobial peptide RG14 obtained in step 2 was dissolved in deionized water to prepare a 1 μmol / mL solution, 10 μL was taken and mixed with an equal volume of a saturated matrix solution (α-cyano-4-hydroxycinnamic acid was dissolved in a 50% acetonitrile solution containing 0.1% trifluoroacetic acid to prepare a saturated solution, centrifuged, and the supernatant was taken) and then measured, and the molecular weight of the antimicrobial peptide RG14 was 1859.22 Da;

[0046] 4. The isoelectric point of the antimicrobial peptide RG14 was determined to be 11.29 by isoelectric focusing electrophoresis, and the amino acid sequence structure of the purified polypeptide was determined by an automatic amino acid sequencer and determined to be Arg-Leu-Phe-Gly-Arg-Leu-Arg-Trp-Ser-Leu-Arg-Arg-Trp-Gly-NH2.

[0047] Example 2

[0048] Antimicrobial activity of antimicrobial peptide RG14

[0049] Definition of minimum inhibitory concentration: the lowest drug concentration that can inhibit bacterial growth and reproduction.

[0050] 2.1 The quantitative antibacterial analysis was performed using the two-fold gradient dilution method. The specific operation is as follows:

[0051] Prepare 1 mg / mL RG14 sample with sterile ultrapure water. Prepare fresh bacterial solution at 1OD 600 =1×10 9 CFU / mL, and dilute the above bacterial solutions with fresh LB liquid medium to adjust the concentration to 2×10 5 CFU / mL.

[0052] Then, 90 μL of physiological saline was added to a sterile 96-well plate in advance, and the prepared RG14 sample (with penicillin and meropenem as positive controls) was added to the first well. The samples to be tested were diluted two-fold in sequence, and 100 μL of 2×10 5 The bacterial solution of 100 CFU / mL was mixed by pipetting and placed in a 37°C constant temperature incubator for overnight culture. Finally, the light absorbance of the bacterial solution at 600 nm was detected by an ELISA reader. The average value of the sample concentrations of the wells where no bacterial growth was detected and the adjacent wells was taken as the minimum inhibitory concentration, i.e., MIC value. The antibacterial activity of the antimicrobial peptide RG14 is shown in Table 1.

[0053] Table 1 Minimum inhibitory concentration of antimicrobial peptide RG14

[0054]

[0055] 2.2 Inoculate Escherichia coli CMCC44102 onto LB solid medium plates and incubate them upside down at 37°C until colonies grow. Pick a single colony with an inoculation loop and inoculate it into LB liquid medium and incubate it in a 37°C shaking incubator until the logarithmic growth phase. Dilute the bacterial solution to 1×10 6 CFU / mL, add the sample to the diluted bacterial solution to make the final concentration 1×, 2× and 4×MIC, the positive control is the corresponding volume of 2×MIC ampicillin, and the negative is the corresponding volume of sterile ultrapure water. The bacterial solution added with the sample was quickly placed in a 37°C shaking incubator and cultured at 150rpm. Take 10μL of the bacterial solution at 0min, 10min, 30min, 60min, 120min and 180min, respectively, and dilute it with sterile saline to 1×10 3 Take 50 μL of the solution and spread it on the LB solid medium plate, then put it in a 37℃ incubator and invert it for 16 hours, and count the colonies. Figure 1 As shown:

[0056] Depend on Figure 1 It can be seen that the antimicrobial peptide RG14 kills bacteria rapidly. At a concentration of 2×MIC, RG14 can kill E. coli within 60 minutes and at a concentration of 4×MIC, RG14 can kill E. coli within 30 minutes, while the positive control ampicillin takes 120 minutes to kill E. coli.

[0057] Example 3

[0058] The hemolytic activity and cytotoxicity of the antimicrobial peptide RG14 were determined in the following steps:

[0059] 3.1 Use normal saline to dilute the washed mouse red blood cells to 10 7 -10 8 / mL, then the red blood cell suspension was mixed with different concentrations of polypeptide samples and incubated at 37℃ for 30min. Centrifuged at 1000rpm for 5min, the supernatant was transferred to a 96-well plate and the ultraviolet absorption value was detected at 540nm. The negative control was normal saline, and the positive control was TritonX-100. As a positive control, the hemolytic activity was proportional to the light absorption value at 540nm. Figure 2 ;

[0060] Depend on Figure 2It can be seen that the light absorption values ​​of the antimicrobial peptide RG14 of the present invention at 540 nm are significantly lower than that of the positive control TritonX-100, and very close to that of the negative control. Therefore, it can be concluded that the hemolytic activity of the antimicrobial peptide RG14 at different concentrations is low.

[0061] 3.2 Activated hacat cells (purchased from Guangzhou Saiku Biotechnology Co., Ltd.) were spread in a culture dish. When the cells grew to cover about 80% of the bottom area of ​​the culture dish, they were digested with 0.25% trypsin, and the cells were gently scraped off, and gently blown to single cells and transferred to a sterile centrifuge tube. Centrifuged at 1000rpm for 5min, the supernatant was discarded, and the cells were resuspended in cell culture medium RPMI1640, blown and mixed, and counted with a hemocytometer. After counting, the cells were diluted to the required cell concentration for the test, which was the seed plate cells.

[0062] Take a sterile 96-well plate, add 10,000 seed cells to each well, and adjust RPMI1640 to a total volume of 100 μL per well. After culturing until the cells adhere to the wall, add peptide samples of various concentration gradients, and set up well plate control and positive control groups. After culturing at 37°C for 24 hours, add 20 μL MTT solution (5 mg / mL, prepared immediately, stored in the dark), continue culturing for 4 hours, then discard the cell culture medium in each well, add 150 μL DMSO (dimethyl sulfoxide), shake slightly to dissolve the crystals, and use a full-wavelength microplate reader to detect the absorbance at 490 nm. The results are as follows: Figure 3 As shown, compared with the control group NC, the antimicrobial peptide RG14 at different concentrations had no cytotoxicity, and the antimicrobial peptide RG14 of the present invention had high safety.

[0063] Example 4

[0064] Stability of antimicrobial peptide RG14

[0065] After the culture medium was supplemented with sodium chloride (150mM), potassium chloride (4.5mM), ammonium chloride (6μM), magnesium chloride (1mM), calcium chloride (2.5mM) and ferric chloride (4μM), the minimum inhibitory concentration was tested again. The blank control was LB culture medium without salt ions added. The results are shown in Table 2. RG14 has good stability in salt ions such as potassium chloride, ammonium chloride, magnesium chloride, and ferric chloride.

[0066] Table 2 Salt ion stability of RG14

[0067]

[0068] The antimicrobial peptide RG14 provided by the present invention can directly kill pathogens, has significant functions and a rapid effect, and RG14 has low hemolytic activity, no cytotoxicity, and high stability, and can be used in the preparation of anti-bacterial infection drugs or skin care products, especially medical beauty products.

[0069] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. An antimicrobial peptide RG14, characterized in that: The antimicrobial peptide RG14 has any of the following amino acid sequences: 1) SEQ ID No. 1; 2) an amino acid sequence in which one or more amino acids in SEQ ID No.1 are substituted, deleted and / or added and which has the same function as SEQ ID No.1; 3) An amino acid sequence that has more than 90% homology with SEQ ID No.1 and has the same function as SEQ ID No.

1.

2. The antimicrobial peptide RG14 according to claim 1, characterized in that: It also includes modifying the antimicrobial peptide RG14.

3. The antimicrobial peptide RG14 according to claim 2, characterized in that: The method comprises performing amidation modification on the C-terminus and / or N-terminus of the antimicrobial peptide RG14.

4. Use of the antimicrobial peptide RG14 according to any one of claims 1 to 3 in the preparation of an antibacterial and bactericidal agent.

5. The application according to claim 4, characterized in that: The antibacterial spectrum of the bacteriostatic and bactericidal agent includes Gram-negative bacteria.

6. The use according to claim 5, characterized in that: The Gram-negative bacteria include at least one of the following: Escherichia coli, Pseudomonas aeruginosa, Shigella castellani, Acinetobacter baumnnii and Clostridium perfringens.

7. A bacteriostatic and bactericidal product, characterized in that: The active ingredient comprises the antimicrobial peptide RG14 according to any one of claims 1 to 3, and also comprises auxiliary materials.

8. The antibacterial and bactericidal product according to claim 7, characterized in that: Active ingredients also include other antibacterial and bactericidal ingredients.

9. The antibacterial and bactericidal product according to claim 8, characterized in that: The other antibacterial and bactericidal components include at least one of the following: antibiotics, proteins, polypeptides, plant extracts and cytokines.

10. The antibacterial and bactericidal product according to claim 7, characterized in that: The types of antibacterial and bactericidal products include medicines and skin care products.

Citation Information

Patent Citations

  • Antimicrobial peptide and application thereof

    CN110078794A

  • Antibacterial peptide TC-14 and application thereof

    CN116715732A

  • Antibacterial peptide blaap-6 and application thereof

    CN117866047A

Cited By

  • Multifunctional protein MZM29 and application thereof

    CN120192383A

  • Antibacterial peptide MAP34B-1 and application thereof

    CN121494935A

  • Antibacterial peptide MAP34B-1 and application thereof

    CN121494935B